So could you comment on the risk assessment as a GN specialist before we talk about the infection prevention part?

Yeah, so...

I think it's important to note when we have these new drugs now and those trials that evaluated and led to FDA approval, accelerated approval of these drugs, we can't always solely rely on a randomized controlled trial to reflect the risk of infection and complication.

I mean, that is not what we would consider a real-world data, so to speak.

So you have your trial, but then as the drug enters the market and people get access to it, usually the scope expands and the types of patients that are getting those drugs that may not have necessarily been qualified or approved for trial.

When we talk about what kind of things to consider, our risk to consider generally, as you might have anticipated learning from just internal medicine training, who's at high risk for infection? Well, people that suffer chronic infections or COPD or progressed kidney disease, all those sort of history of malignancy, all those sort of things that you will use your sort of clinical gestalt to say, oh boy, this patient is potentially at high risk.

And then they're owed at least at baseline the vaccinations of things like haemophilus and pneumo protection, meningitis protection, all those things should be standardized.

What is the most common question you get asked as a GN specialist in this infection prevention era? It's